Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567191 | 0.88 | PDPK1 (0.50) | IDO1PDPK1ADRA1A | |
| SCHEMBL8893702 | 0.81 | IDO1 (0.49) | IDO1HTTALDH1A1ADRA2AADRA1A | |
| SCHEMBL29663637 | 0.81 | IDO1 (0.49) | IDO1GID4HTTALDH1A1XBP1 | |
| SCHEMBL9159890 | 0.81 | IDO1 (0.49) | IDO1GID4HTTALDH1A1XBP1 | |
| SCHEMBL1567118 | 0.81 | IDO1 (0.49) | IDO1HTTALDH1A1ADRA2AADRA1A | |
| SCHEMBL8699708 | 0.81 | IDO1 (0.49) | IDO1GID4HTTALDH1A1XBP1 | |
| SCHEMBL782544 | 0.81 | IDO1 (0.49) | IDO1GID4HTTALDH1A1XBP1 | |
| SCHEMBL10648765 | 0.80 | IDO1 (0.45) | IDO1PDPK1GID4HTTALDH1A1 | |
| SCHEMBL361005 | 0.78 | IDO1 (0.46) | IDO1HTTALDH1A1ADRA2AADRA1A | |
| SCHEMBL7538343 | 0.77 | IDO1 (0.45) | IDO1HTTALDH1A1XBP1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780318-B1 | PROCESS FOR THE PRODUCTION OF N-SUBSTITUTED 2-(ACETYLAMINO)-N'-BENZYL-3-METHOXYPROPANAMIDES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-08-26 | — | — | EP | claimed |
| EP-2780318-A1 | PROCESS FOR THE PRODUCTION OF N-SUBSTITUTED 2-(ACETYLAMINO)-N'-BENZYL-3-METHOXYPROPANAMIDES | Sanofi-Aventis Deutschland GmbH (DE) | 2014-09-24 | — | — | EP | claimed |
| WO-2013072330-A1 | PROCESS FOR THE PRODUCTION OF N-SUBSTITUTED 2-(ACETYLAMINO)-N'-BENZYL-3-METHOXYPROPANAMIDES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-05-23 | — | — | WO | claimed |
| EP-2780318-B1 | PROCESS FOR THE PRODUCTION OF N-SUBSTITUTED 2-(ACETYLAMINO)-N'-BENZYL-3-METHOXYPROPANAMIDES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2780318-A1 | PROCESS FOR THE PRODUCTION OF N-SUBSTITUTED 2-(ACETYLAMINO)-N'-BENZYL-3-METHOXYPROPANAMIDES | Sanofi-Aventis Deutschland GmbH (DE) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072330-A1 | PROCESS FOR THE PRODUCTION OF N-SUBSTITUTED 2-(ACETYLAMINO)-N'-BENZYL-3-METHOXYPROPANAMIDES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-05-23 | — | — | WO | disclosed |
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1323726-A1 | ERYTHROMYCIN DERIVATIVES AND MEDICINES CONTAINING THE SAME | HOKURIKU SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | MAPRE1, MAPRE2, MRPS27 | IDO1 4102/4885PDPK1 4244/4885GID4 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.